Your browser doesn't support javascript.
loading
Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
Neoh, C F; Senol, E; Kara, A; Dinleyici, E C; Turner, S J; Kong, D C M.
Affiliation
  • Neoh CF; Collaborative Drug Discovery Research (CDDR) Group, Faculty of Pharmacy, Universiti Teknologi MARA, 42300, Puncak Alam, Selangor, Malaysia.
  • Senol E; Department of Infectious Diseases, Gazi University, Ankara, Turkey.
  • Kara A; Department of Paediatric Infectious Diseases, Hacettepe University, Ankara, Turkey.
  • Dinleyici EC; Department of Paediatrics, Faculty of Medicine, Eskisehir Osmangazi University, 26480, Eskisehir, Turkey.
  • Turner SJ; Norvatis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA.
  • Kong DCM; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia. david.kong@monash.edu.
Eur J Clin Microbiol Infect Dis ; 37(3): 537-544, 2018 Mar.
Article in En | MEDLINE | ID: mdl-29185089
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Models, Economic / Echinocandins / Lipopeptides / Candidemia / Antifungal Agents Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Limits: Humans Country/Region as subject: Asia Language: En Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Models, Economic / Echinocandins / Lipopeptides / Candidemia / Antifungal Agents Type of study: Clinical_trials / Health_economic_evaluation / Prognostic_studies Limits: Humans Country/Region as subject: Asia Language: En Year: 2018 Type: Article